alpha-aminopyridine has been researched along with Bone Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Z; Chen, J; Chen, Q; Gu, H; Guo, X; He, D; He, H; He, J; Huang, X; Wang, G; Yan, H; Yang, Y; Yi, Q; Zhang, E; Zhao, Y | 1 |
| Fitter, S; Gan, ZY; Martin, SK; To, LB; Zannettino, AC | 1 |
2 other study(ies) available for alpha-aminopyridine and Bone Diseases
| Article | Year |
|---|---|
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Bone Diseases; Bone Resorption; Cell Cycle Checkpoints; Cell Line, Tumor; Cells, Cultured; Histone Deacetylase Inhibitors; Humans; Mice; Multiple Myeloma; Osteoblasts; Osteoclasts | 2018 |
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Bone Diseases; Cell Cycle; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, Inbred C57BL; Morpholines; Multiple Myeloma; Osteoclasts; Osteolysis; Phosphoinositide-3 Kinase Inhibitors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |